Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 15/20 | 0.64 |
| ▸ | MTOR | P42345 | 3/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695285 | 0.88 | MAP3K12 (0.66) | MAP3K12 | |
| SCHEMBL20115399 | 0.85 | MAP3K12 (0.60) | MAP3K12PIK3CA | |
| SCHEMBL21695280 | 0.83 | MAP3K12 (0.60) | MAP3K12PIK3CA | |
| SCHEMBL20147765 | 0.82 | MAP3K12 (0.60) | MAP3K12PIK3CA | |
| SCHEMBL16013467 | 0.80 | MTOR (0.71) | MAP3K12MTORPIK3R1PIK3CAPIK3CD | |
| SCHEMBL21695290 | 0.79 | MAP3K12 (0.61) | MAP3K12PIK3CA | |
| SCHEMBL21695315 | 0.78 | MAP3K12 (0.62) | MAP3K12PIK3CA | |
| SCHEMBL16224397 | 0.78 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL20340991 | 0.77 | MAP3K12 (0.85) | MAP3K12 | |
| SCHEMBL21695275 | 0.77 | MAP3K12 (0.64) | MAP3K12PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | MAP3K12 1980/4885MTOR 3221/4885PIK3R1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.